Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of CRS Profile for Glofitamab + Gemcitabine + Oxaliplatin in Relapsed/Refractory Aggressive B-Cell NHL
2024-516791-15-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Mar 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in aggressive B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 1 more, sponsored by Roche. Primary endpoints: Incidence of Grade 2 or higher CRS and Incidence of any Grade CRS. Planned start Mar 2025; status: authorised.
02
Drugs
glofitamab
03
Conditions
aggressive B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomaHigh-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBL-DH)
Beyond the preview
Go deeper on 2024-516791-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516791-15-00.